Shaw Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
Kite Gilead’s Kite shortens Yescarta manufacturing time with FDA nod
Kite Receives U.S. FDA Approval of Manufacturing Process Change
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023
Analyses Presented at ASH Support Kite’s Tecartus in Patients With Blood Cancers
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential
Arcellx, Kite aim to keep chipping away at Carvykti advantage
Gilead Sciences' Kite Pharma cell therapy unit is undergoing a business review that will result in layoffs to about 7% of the organization’s workforce.
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer